# Demcon Hemics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/demcon-hemics

- Industry: Medical Devices & Equipment
- Headquarters: Netherlands
- Website: www.hemics.com
- Latest round: Series B (Jan 9, 2015)
- Investors on record: 4

## About

Demcon Hemics BV is a Netherlands-based developer of medical devices focused on the assessment and management of Rheumatoid Arthritis, particularly through their innovative HandScan technology that detects inflammation non-invasively.Founded in 2011 in the Netherlands, Demcon Hemics BV specializes in medical device technology aimed at diagnosing and managing Rheumatoid Arthritis. The company has not undergone any significant pivots or changes since its inception. It was established independently and not as a subsidiary or through a merger. The company has completed a total of three deals, with the latest funding round being a Grant worth EUR 0.050 mn led by EASME on January 9, 2015.Demcon Hemics specializes in developing innovative medical devices for the assessment and management of Rheumatoid Arthritis (RA). The company's flagship product, the HandScan, utilizes patented Optical Inflammation Detection technology to provide non-invasive, rapid, and objective quantification of inflammation levels in the joints of the hands and wrists. By applying a pressure cuff to induce blood pooling, the device differentiates between inflamed and healthy tissues using red and near-infrared light to measure changes in light transmission. This process generates a 2D image that visualizes vascular responses, thereby aiding rheumatologists in effectively monitoring disease activity and guiding treatment plans. Hemics primarily serves healthcare providers, including hospitals and clinics, that focus on rheumatology, and its products are marketed in various international markets, particularly across Europe and North America.Hemics operates under a transactional model that incorporates direct sales to healthcare providers and institutions that utilize its medical imaging technology. The company engages in B2B transactions, providing its HandScan devices to hospitals and clinics, which can integrate the technology into their existing healthcare systems. Revenue is generated through the sale of the HandScan units, and potentially through service agreements that may include maintenance and support options for these devices. The pricing structure for these devices reflects their advanced technology and clinical utility, positioning them as essential tools for rheumatologists seeking effective methods to monitor and treat RA. Hemics maintains strategic partnerships with healthcare institutions to further enhance the accessibility and integration of its products in clinical settings.Demcon Hemics BV is focused on expanding its product offerings and market reach. The company plans to introduce new products that enhance the capabilities of the HandScan technology in the upcoming years. Additionally, Hemics is targeting expansion into new geographic regions, particularly in emerging markets throughout Europe and North America, by the end of 2024. The recent Grant funding of EUR 0.050 mn from EASME will be utilized to support product development and market entry strategies, enabling the company to further its mission of providing innovative solutions for Rheumatoid Arthritis management.

## Funding rounds

- Series B, Jan 9, 2015 — Point-One Starter, Thuja Capital, BOM Brabant Ventures, DFZ Participaties
- Series A, Sep 20, 2011 — Point-One Starter, Thuja Capital, BOM Brabant Ventures

## Investors

- Point-One Starter (https://capitalatlas.ai/funds/point-one-starter) — Series A, Series B
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A, Series B
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Series A, Series B
- DFZ Participaties — Series B